Human medicines European public assessment report (EPAR): Denosumab Intas, denosumab, Date of authorisation: 17/11/2025, Status: Authorised

CHMP opinions on consultation procedures

Consultation on an ancillary medicinal substance incorporated in a medical device - Gynemed GmbH & Co. KG HSA-containing ART media

Consideration on core requirements for RMPs of COVID-19 vaccines

Human medicines European public assessment report (EPAR): Jivi, damoctocog alfa pegol, Date of authorisation: 22/11/2018, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Sogroya, somapacitan, Date of authorisation: 31/03/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 69, Status: Authorised

Availability of medicines before and during crises

Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Dengvaxia, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 12/12/2018, Revision: 7, Status: Withdrawn